Drugs / RUPLIZUMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001789 | Jun 1999 → May 2000 | lupus nephritis, membranoproliferative glomerulonephritis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 2 | NCT00001857 | May 1999 → Apr 2000 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUPLIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108767 ↗ |
| Known as | Antova | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108767 ↗ |
| Known as | Antova TM | “the drug presently known as BG9588 (Antova TM) can reduce the incidence of organ rejection following kidney transplants in humans.” NCT00001857 ↗ |
| Known as | BG9588 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001789 ↗ |
| Known as | HU-5C8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108767 ↗ |
| Action | Inhibit | “thereby blocks the CD40L/CD40 interaction” NCT00001789 ↗1“CD40 ligand inhibitor” CHEMBL2108767 ↗ |
| Modality | Monoclonal antibody | “BG9588 is a recombinant humanized monoclonal antibody” NCT00001789 ↗ |
| Route | Intravenous | “20 mg/kg BG9588 by IV infusion” NCT00001789 ↗ |
| Target | CD40LG | “CD40 ligand inhibitor” CHEMBL2108767 ↗ |